TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
1.920
-0.060 (-3.03%)
At close: Mar 3, 2025, 4:00 PM
1.850
-0.070 (-3.65%)
Pre-market: Mar 4, 2025, 8:18 AM EST
TransCode Therapeutics Employees
TransCode Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 9 or -47.37% compared to the previous year.
Employees
10
Change (1Y)
-9
Growth (1Y)
-47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,492,656
Market Cap
1.34M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10 | -9 | -47.37% |
Dec 31, 2022 | 19 | 10 | 111.11% |
Dec 31, 2021 | 9 | 3 | 50.00% |
Dec 31, 2020 | 6 | 0 | - |
Dec 31, 2019 | 6 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
RNAZ News
- 6 days ago - TransCode Therapeutics, Inc. Announces Results of Special Meeting - PRNewsWire
- 26 days ago - TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - PRNewsWire
- 27 days ago - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - PRNewsWire
- 7 weeks ago - TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial - PRNewsWire
- 2 months ago - Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements - PRNewsWire
- 2 months ago - TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial - PRNewsWire
- 3 months ago - TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split - GlobeNewsWire
- 3 months ago - TransCode Therapeutics, Inc. Announces $8 Million Private Placement - GlobeNewsWire